Obstructive Sleep Apnea Pipeline Review | Latest Drug Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma

Posted on
by

Obstructive Sleep Apnea Pipeline Review | Latest Drug Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Axsome Therapeutics/Jazz Pharma, Bioprojet Pharma, Taisho Pharma
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obstructive Sleep Apnea pipeline constitutes 20+ key companies continuously working towards developing 20+ Obstructive Sleep Apnea treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Obstructive Sleep Apnea Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Obstructive Sleep Apnea Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obstructive Sleep Apnea Market.

 

Some of the key takeaways from the Obstructive Sleep Apnea Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Obstructive Sleep Apnea treatment therapies with a considerable amount of success over the years. 
  • Obstructive Sleep Apnea companies working in the treatment market are Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others, are developing therapies for the Obstructive Sleep Apnea treatment 
  • Emerging Obstructive Sleep Apnea therapies in the different phases of clinical trials are- AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others are expected to have a significant impact on the Obstructive Sleep Apnea market in the coming years.   
  • In January 2023, Pitolisant was the subject of a Phase III investigation by Aculys Pharma in Japan for the treatment of individuals with OSA and EDS.
  • In June 2022, The trial was started by Eli Lilly and Company under the name “A Master Protocol to Investigate theEfficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: ARandomized, Double-Blind, Placebo-Controlled Trial”.

 

Obstructive Sleep Apnea Overview

The breathing disorder known as obstructive sleep apnea (OSA) occurs when the upper airway repeatedly becomes blocked while a person is asleep. When something stops all or part of the upper airway while a person is sleeping, it causes obstructed sleep apnea.

 

Get a Free Sample PDF Report to know more about Obstructive Sleep Apnea Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-pipeline-insight

 

Emerging Obstructive Sleep Apnea Drugs Under Different Phases of Clinical Development Include:

  • AD109: Apnimed
  • Tirzepatide: Eli Lilly and Company
  • AD113: Apnimed
  • SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
  • OZAWADE (Pitolisant): Bioprojet Pharma
  • TS-142: Taisho Pharmaceutical Co., Ltd.
  • TAK-925: Takeda
  • BAY 2586116: Bayer
  • Sulthiame: Desitin Arzneimittel GmbH
  • Lemborexant : Eisai

 

Obstructive Sleep Apnea Route of Administration

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Obstructive Sleep Apnea Molecule Type

Obstructive Sleep Apnea Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Obstructive Sleep Apnea Pipeline Therapeutics Assessment

  • Obstructive Sleep Apnea Assessment by Product Type
  • Obstructive Sleep Apnea By Stage and Product Type
  • Obstructive Sleep Apnea Assessment by Route of Administration
  • Obstructive Sleep Apnea By Stage and Route of Administration
  • Obstructive Sleep Apnea Assessment by Molecule Type
  • Obstructive Sleep Apnea by Stage and Molecule Type

 

DelveInsight’s Obstructive Sleep Apnea Report covers around 20+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Obstructive Sleep Apnea product details are provided in the report. Download the Obstructive Sleep Apnea pipeline report to learn more about the emerging Obstructive Sleep Apnea therapies

 

Some of the key companies in the Obstructive Sleep Apnea Therapeutics Market include:

Key companies developing therapies for Obstructive Sleep Apnea are – Apnimed, Eli Lilly and Company, Therapix Biosciences, Bioprojet Pharma, Axsome Therapeutics/ Jazz Pharmaceuticals and others.

 

Obstructive Sleep Apnea Pipeline Analysis:

The Obstructive Sleep Apnea pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
  • Obstructive Sleep Apnea key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Obstructive Sleep Apnea drugs and therapies

 

Obstructive Sleep Apnea Pipeline Market Drivers

  • Increase in prevalence of Obstructive Sleep Apnea (OSA), rising awareness of the disorder are some of the important factors that are fueling the Obstructive Sleep Apnea Market.

 

Obstructive Sleep Apnea Pipeline Market Barriers

  • However, lack of Approved Drugs, complexity of OSA pathogenesis and other factors are creating obstacles in the Obstructive Sleep Apnea Market growth.

 

Scope of Obstructive Sleep Apnea Pipeline Drug Insight    

  • Coverage: Global
  • Key Obstructive Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others
  • Key Obstructive Sleep Apnea Therapies: AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others
  • Obstructive Sleep Apnea Therapeutic Assessment: Obstructive Sleep Apnea current marketed and Obstructive Sleep Apnea emerging therapies
  • Obstructive Sleep Apnea Market Dynamics: Obstructive Sleep Apnea market drivers and Obstructive Sleep Apnea market barriers 

 

Request for Sample PDF Report for Obstructive Sleep Apnea Pipeline Assessment and clinical trials

 

Table of Contents 

1. Obstructive Sleep Apnea Report Introduction

2. Obstructive Sleep Apnea Executive Summary

3. Obstructive Sleep Apnea Overview

4. Obstructive Sleep Apnea- Analytical Perspective In-depth Commercial Assessment

5. Obstructive Sleep Apnea Pipeline Therapeutics

6. Obstructive Sleep Apnea Late Stage Products (Phase II/III)

7. Obstructive Sleep Apnea Mid Stage Products (Phase II)

8. Obstructive Sleep Apnea Early Stage Products (Phase I)

9. Obstructive Sleep Apnea Preclinical Stage Products

10. Obstructive Sleep Apnea Therapeutics Assessment

11. Obstructive Sleep Apnea Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Obstructive Sleep Apnea Key Companies

14. Obstructive Sleep Apnea Key Products

15. Obstructive Sleep Apnea Unmet Needs

16 . Obstructive Sleep Apnea Market Drivers and Barriers

17. Obstructive Sleep Apnea Future Perspectives and Conclusion

18. Obstructive Sleep Apnea Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services